截至9月30日，超研股份股东户数1.70万，较上期减少23.90%；人均流通股3438股，较上期增加 39.99%。2025年1月-9月，超研股份实现营业收入2.54亿元，同比减少2.90%；归母净利润8894.45万元， 同比减少3.66%。 分红方面，超研股份A股上市后累计派现4368.96万元。 12月18日，超研股份涨1.07%，成交额2351.88万元。两融数据显示，当日超研股份获融资买入额130.33 万元，融资偿还196.65万元，融资净买入-66.32万元。截至12月18日，超研股份融资融券余额合计 7792.63万元。 融资方面，超研股份当日融资买入130.33万元。当前融资余额7776.93万元，占流通市值的6.11%。 融券方面，超研股份12月18日融券偿还400.00股，融券卖出700.00股，按当日收盘价计算，卖出金额 1.53万元；融券余量7200.00股，融券余额15.70万元。 资料显示，汕头市超声仪器研究所股份有限公司位于广东省汕头市金砂路77号，成立日期1982年11月15 日，上市日期2025年1月22日，公司主营业务涉及专业从事医学影像设备、工业无损检测设备的研发、 生 ...

异动分析 来源：新浪证券-红岸工作室 12月18日，超研股份涨1.07%，成交额2351.88万元，换手率1.85%，总市值93.38亿元。 区间今日近3日近5日近10日近20日主力净流入28.43万-225.13万-437.22万-818.84万-2505.42万 宠物经济+医疗器械概念+水利+人民币贬值受益+注册制次新股 1、2025年3月8日官微：SIUI于3月3日至5日参加了第97届WVC年会。在此次盛会上，SIUI展出了我们 在宠物、马匹和家畜方面的创新兽用医学影像成果，与行业专家就动物医疗保健的发展进行了交流，并 在与一线从业者的交流中获得了宝贵的用户见解。 2、汕头市超声仪器研究所股份有限公司的主营业务是从事医学影像设备、工业无损检测设备的研发、 生产和销售；公司主要产品包括掌上式无线彩超、便携式彩超、推车式彩超、全容积乳腺超声成像系 统、全数字超声显像诊断仪、便携式X射线机、便携式数字化X射线摄影系统、数字超声探伤仪、超声 成像检测仪、自动检测装置和探头、医用超声探头、工业无损检测探头； 3、2025年7月24日互动易：公司的工业超声产品，在水电工程方面主要应用于管道管线，发电汽轮机， 压力容 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Chao Yan Co., Ltd., particularly in the medical device industry, where it has a high PE ratio compared to industry averages [1][2] - As of December 12, Chao Yan Co., Ltd. closed at 22.3 yuan, with a rolling PE ratio of 67.17 times and a total market capitalization of 9.552 billion yuan [1] - The company ranks 102nd in the medical device industry, which has an average PE ratio of 50.65 times and a median of 38.17 times [1][2] Group 2 - As of the third quarter of 2025, nine institutions hold shares in Chao Yan Co., Ltd., with a total of 4.3483 million shares valued at 107 million yuan [1] - The main business of Chao Yan Co., Ltd. includes the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [1] - The latest financial results for the third quarter of 2025 show that the company achieved an operating income of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit of 88.9445 million yuan, a year-on-year decrease of 3.66%, with a sales gross margin of 73.20% [1]

来源：新浪证券-红岸工作室 12月12日，超研股份涨1.09%，成交额2288.66万元，换手率1.76%，总市值95.52亿元。 今日主力净流入-127.43万，占比0.06%，行业排名75/132，连续3日被主力资金减仓；所属行业主力净流 入80.13万，当前无连续增减仓现象，主力趋势不明显。 区间今日近3日近5日近10日近20日主力净流入-127.43万-302.48万-344.32万-871.74万-3291.96万 异动分析 宠物经济+医疗器械概念+水利+人民币贬值受益+注册制次新股 1、2025年3月8日官微：SIUI于3月3日至5日参加了第97届WVC年会。在此次盛会上，SIUI展出了我们 在宠物、马匹和家畜方面的创新兽用医学影像成果，与行业专家就动物医疗保健的发展进行了交流，并 在与一线从业者的交流中获得了宝贵的用户见解。 2、汕头市超声仪器研究所股份有限公司的主营业务是从事医学影像设备、工业无损检测设备的研发、 生产和销售；公司主要产品包括掌上式无线彩超、便携式彩超、推车式彩超、全容积乳腺超声成像系 统、全数字超声显像诊断仪、便携式X射线机、便携式数字化X射线摄影系统、数字超声探伤仪、超声 ...

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4327.65 points, down 0.28%, with a trading volume of HKD 7.682 billion and a turnover rate of 0.9% [1] - Among the index constituents, 21 stocks rose while 36 stocks fell, with Kewei Medical leading the gainers at a 4.14% increase and Xianjian Technology leading the decliners at a 9.14% decrease [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56%, latest price at HKD 198.00, and a market cap of HKD 240.063 billion, down 0.36% [1] - Yier Eye Hospital (sz300015) with a weight of 11.62%, latest price at HKD 11.23, and a market cap of HKD 104.724 billion, down 0.62% [1] - Lejin Medical (sz300003) with a weight of 4.85%, latest price at HKD 15.64, and a market cap of HKD 28.831 billion, down 0.64% [1] - Aimeike (sz300896) with a weight of 4.80%, latest price at HKD 143.25, and a market cap of HKD 43.346 billion, up 1.47% [1] - Yuyue Medical (sz002223) with a weight of 4.66%, latest price at HKD 35.68, and a market cap of HKD 35.768 billion, up 0.17% [1] - Yingke Medical (sz300677) with a weight of 3.64%, latest price at HKD 41.76, and a market cap of HKD 27.360 billion, down 0.17% [1] - Furuijia (sz300049) with a weight of 3.59%, latest price at HKD 69.33, and a market cap of HKD 18.371 billion, down 0.82% [1] - Meinian Health (sz002044) with a weight of 3.58%, latest price at HKD 5.09, and a market cap of HKD 19.924 billion, up 0.39% [1] - Sinopharm Holdings (hk01099) with a weight of 3.35%, latest price at HKD 18.15, and a market cap of HKD 56.638 billion, down 0.40% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63%, latest price at HKD 12.23, and a market cap of HKD 26.434 billion, down 3.24% [1] Capital Flow Analysis - The index constituents experienced a net outflow of HKD 382 million from institutional investors, while retail investors saw a net inflow of HKD 329 million [1] - Notable individual stock capital flows include: - Meinian Health (sz002044) with a net inflow of HKD 23.6308 million from institutional investors [2] - Aimeike (sz300896) with a net inflow of HKD 5.8353 million from institutional investors [2] - Yier Eye Hospital (sz300015) with a net outflow of HKD 20.7620 million from retail investors [2]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [3][4]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business segments include medical ultrasound (71.16% of revenue), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other supplementary products (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8]. - As of September 30, 2025, the company's overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [3]. Market Activity - On December 10, the company's stock price increased by 0.09%, with a trading volume of 17.43 million yuan and a turnover rate of 1.35%, resulting in a total market capitalization of 9.517 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net outflow of 1.4365 million yuan on the same day [4][5]. Shareholder Structure - As of September 30, 2025, the company had 17,000 shareholders, a decrease of 23.90% from the previous period, with an average of 3,438 shares held per shareholder, an increase of 39.99% [7]. - The largest shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which decreased by 388,200 shares compared to the previous period [9].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Chao Yan Co., Ltd., particularly in the medical device industry, where it has a high PE ratio compared to industry averages [1][2] - As of November 24, Chao Yan Co., Ltd. closed at 22.9 yuan, with a PE ratio of 68.98 times, and a total market capitalization of 9.809 billion yuan [1] - The company experienced a net outflow of 1.1232 million yuan in principal funds on November 24, with a total outflow of 17.8707 million yuan over the past five days [1] Group 2 - Chao Yan Co., Ltd. specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with key products including medical ultrasound imaging devices and portable DR [1] - The latest financial results for the third quarter of 2025 show that the company achieved an operating income of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit of 88.9445 million yuan, down 3.66% year-on-year, with a gross profit margin of 73.20% [1] - In terms of industry comparison, the average PE ratio for the medical device sector is 52.19 times, with a median of 40.14 times, positioning Chao Yan Co., Ltd. at 101st in the industry ranking [1][2]

Core Insights - Chao Yan Co., Ltd. experienced a stock price increase of 1.45% on November 12, with a trading volume of 87.1 million yuan [1] - The company reported a financing net purchase of 1.34 million yuan on the same day, with a total financing and securities balance of 92.95 million yuan [1] - As of September 30, 2025, the company recorded a revenue of 254 million yuan, a year-on-year decrease of 2.9%, and a net profit of 88.94 million yuan, down 3.66% year-on-year [2] Financing and Trading Data - On November 12, Chao Yan Co., Ltd. had a financing buy amount of 8.22 million yuan and a financing repayment of 6.89 million yuan, resulting in a net financing purchase of 1.34 million yuan [1] - The current financing balance is 92.72 million yuan, accounting for 6.30% of the circulating market value [1] - The company had a securities lending balance of 22.96 thousand yuan, with a remaining amount of 9,100 shares [1] Shareholder and Institutional Holdings - As of September 30, 2025, the number of shareholders decreased by 23.9% to 17,000, while the average circulating shares per person increased by 39.99% to 3,438 shares [2] - The largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.52 million shares, a decrease of 388,200 shares from the previous period [3] - New institutional shareholders include Yuanxin Yongfeng Medical Health A, holding 650,100 shares, and Medical Device ETF, holding 350,100 shares [3] Business Overview - Chao Yan Co., Ltd. specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, recognized as a national key high-tech enterprise [1] - The company's revenue composition includes 71.16% from medical ultrasound, 17.30% from industrial ultrasound, 5.72% from accessories, 4.56% from X-ray, and 1.26% from other sources [1]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, production, and sales of medical imaging and industrial non-destructive testing equipment, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [3][4]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business segments include medical ultrasound (71.16% of revenue), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8][9]. - As of September 30, 2025, the company had a total market capitalization of 10.623 billion yuan [1]. Market Dynamics - The company benefits from trends in the pet economy, medical devices, and water conservancy, as well as the depreciation of the RMB, which has positively impacted its overseas revenue, accounting for 55.26% of total revenue [3][4]. - The stock has experienced a recent increase in trading activity, with a turnover rate of 2.32% and a trading volume of 33.54 million yuan on November 6 [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 23.90% to 17,000, while the average number of circulating shares per person increased by 39.99% to 3,438 shares [7]. - The largest shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which represents a decrease of 388,200 shares compared to the previous period [9].

Core Insights - On November 3, Chao Yan Co., Ltd. saw a stock increase of 1.14% with a trading volume of 46.31 million yuan [1] - The company reported a financing buy-in of 6.08 million yuan and a net financing buy of 2.97 million yuan on the same day [1] - As of November 3, the total financing and securities lending balance for Chao Yan Co. was 93.82 million yuan [1] Financial Performance - For the period from January to September 2025, Chao Yan Co. achieved a revenue of 254 million yuan, a year-on-year decrease of 2.90% [2] - The net profit attributable to shareholders for the same period was 88.94 million yuan, reflecting a year-on-year decline of 3.66% [2] - Cumulative cash dividends paid by the company since its A-share listing amounted to 43.69 million yuan [2] Shareholder Structure - As of September 30, 2025, the number of shareholders for Chao Yan Co. was 17,000, a decrease of 23.90% from the previous period [2] - The largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.52 million shares, down by 388,200 shares from the previous period [3] - New institutional shareholders include Yuanxin Yongfeng Medical Health A, holding 650,100 shares [3]